{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:09:35Z","timestamp":1785413375396,"version":"3.56.0"},"reference-count":30,"publisher":"IMR Press","issue":"7","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Neurol."],"abstract":"<jats:p>Background:Plasma phosphorylated tau 217 protein (p-tau217p) has recently been proposed as a useful biomarker for the early diagnosis of Alzheimer\u2019s disease (AD). However, local validation is recommended because of the potential influence of clinical, analytical, and preanalytical factors on assay performance.Methods:Between 2021 and 2024, we evaluated patients with amnestic mild cognitive impairment (aMCI) through clinical history, neurological and neuropsychological examination, blood sampling for biobanking, brain imaging, and lumbar puncture, among other diagnostic tests. In September 2025, p-tau217p levels were measured simultaneously using the LUMIPULSE immunoassay (Fujirebio). The diagnostic validity, reproducibility, receiver operating characteristic (ROC) curve performance, correlation with cerebrospinal fluid (CSF) biomarkers, and influence of clinical and analytical variables were evaluated in this study.Results:Among the 108 aMCI patients included, 66 met the criteria for clinic-biological AD, while the remainder had alternative clinical diagnoses. Using a two-threshold approach, p-tau217p levels \u22650.19 yielded a sensitivity of 88% and a positive predictive value of 83% for identifying AD. Levels \u22650.39 showed a specificity of 91% and a positive predictive value of 90% for the same purpose. Intermediate values (0.20\u20130.38) achieved a specificity of 83%. The intraclass correlation coefficient for the assay reproducibility was 0.97. The ROC curve for p-tau217p demonstrated an area under the curve of 0.86 for diagnosing AD. P-tau217p correlated more strongly with CSF p-tau181 (\u03c1 = 0.63; p &lt; 0.01) than with CSF A\u03b21-42 (\u03c1 = \u20130.40; p &lt; 0.01). Finally, a reduced glomerular filtration rate was associated with a significant increase in p-tau217p levels (p &lt; 0.006).Conclusions:In our setting, p-tau217p measurement showed a high validity for the diagnosis of prodromal AD, which is consistent with the recent neurological literature. The assay showed high reproducibility, although results may be influenced by renal function. P-tau217p correlated more strongly with CSF p-tau181 than with CSF A\u03b21-42.<\/jats:p>","DOI":"10.31083\/rn50619","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:50:09Z","timestamp":1785412209000},"source":"Crossref","is-referenced-by-count":0,"title":["Validation of Plasma p-tau217 as a Biomarker of Prodromal Alzheimer\u2019s Disease"],"prefix":"10.31083","volume":"81","author":[{"given":"Victoria","family":"Monge-Garc\u00eda","sequence":"first","affiliation":[{"name":"Physical Medicine and Rehabilitation Section, Marina Baixa Hospital, 03570 La Vila Joiosa, Alicante, Spain"},{"name":"Sanitary and Biomedical Research Institute (ISABIAL), 03010 Alicante, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sof\u00eda","family":"Lorenzo-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Sanitary and Biomedical Research Institute (ISABIAL), 03010 Alicante, Spain"},{"name":"Department of Clinical Analysis, University General Hospital Dr. Balmis, 03010 Alicante, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda-Carmen","family":"Bernal-Soriano","sequence":"additional","affiliation":[{"name":"Department of Clinical Analysis, University General Hospital Dr. Balmis, 03010 Alicante, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Torrella-Esteban","sequence":"additional","affiliation":[{"name":"Department of Clinical Analysis, University General Hospital Dr. Balmis, 03010 Alicante, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Monge-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Department of Neurology, St. Augustinos Hospital, 52355 D\u00fcren, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"S\u00e1nchez-Pay\u00e1","sequence":"additional","affiliation":[{"name":"Sanitary and Biomedical Research Institute (ISABIAL), 03010 Alicante, Spain"},{"name":"Preventive Section, University General Hospital Dr. Balmis, 03010 Alicante, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8698-7699","authenticated-orcid":true,"given":"Jos\u00e9-Antonio","family":"Monge-Argil\u00e9s","sequence":"additional","affiliation":[{"name":"Sanitary and Biomedical Research Institute (ISABIAL), 03010 Alicante, Spain"},{"name":"Department of Neurology, University General Hospital Dr. Balmis, 03010 Alicante, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984; 34: 939\u2013944.","DOI":"10.1212\/wnl.34.7.939"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Dubois B, Villain N, Schneider L, Fox N, Campbell N, Galasko D, et al. Alzheimer Disease as a Clinical-Biological Construct-An International Working Group Recommendation. JAMA Neurology. 2024; 81: 1304\u20131311.","DOI":"10.1001\/jamaneurol.2024.3770"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 2018; 14: 535\u2013562.","DOI":"10.1016\/j.jalz.2018.02.018"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Bjerke M, Engelborghs S. Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis. Journal of Alzheimer's Disease : JAD. 2018; 62: 1199\u20131209.","DOI":"10.3233\/JAD-170680"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Ashton NJ, Brum WS, Di Molfetta G, Benedet AL, Arslan B, Jonaitis E, et al. Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. JAMA Neurology. 2024; 81: 255\u2013263.","DOI":"10.1001\/jamaneurol.2023.5319"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Lombardi G, Pancani S, Manca R, Mitolo M, Baiardi S, Massa F, et al. Role of Blood P-Tau Isoforms (181, 217, 231) in Predicting Conversion from MCI to Dementia Due to Alzheimer's Disease: A Review and Meta-Analysis. International Journal of Molecular Sciences. 2024; 25: 12916.","DOI":"10.3390\/ijms252312916"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Vanderlip CR, Stark CEL. Integrating plasma p-tau217 and digital cognitive assessments for early detection in Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 2025; 21: e70355.","DOI":"10.1002\/alz.70355"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Jack CR Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 2024; 20: 5143\u20135169.","DOI":"10.1002\/alz.13859"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Hellquist E, Janelidze S, Weidung B, Franzon K, Giedraitis V, Ingelsson M, et al. Plasma p-tau217 correlates strongly with cerebrospinal fluid A\u03b242 and increases over a ten-year period in amyloid-positive, non-demented very old men. Journal of Alzheimer's Disease : JAD. 2025; 108: 1778\u20131789.","DOI":"10.1177\/13872877251390387"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Imperiale D, Marcinn\u00f2 A, Atzori C, Angeloro DP, Murgioni A, Bagatin A, et al. Plasma pTau217\/A\u03b242 and pTau217 outperform pTau181\/A\u03b242 and pTau181 in predicting cerebrospinal fluid amyloid positivity: A real-world retrospective study. Journal of Alzheimer's Disease : JAD. 2025; 108: 1961\u20131971.","DOI":"10.1177\/13872877251390897"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Arranz J, Zhu N, Rubio-Guerra S, Rodr\u00edguez-Baz \u00cd, Ferrer R, Carmona-Iragui M, et al. Diagnostic performance of plasma pTau217, pTau181, A\u03b21-42 and A\u03b21-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease. Alzheimer's Research & Therapy. 2024; 16: 139.","DOI":"10.1186\/s13195-024-01513-9"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Arranz J, Ferrer R, Zhu N, Rubio-Guerra S, Rodr\u00edguez-Baz \u00cd, Arriola-Infante JE, et al. Prospective evaluation of plasma pTau217 stability for the detection of Alzheimer's disease in a tertiary memory clinic. Alzheimer's Research & Therapy. 2025; 17: 150.","DOI":"10.1186\/s13195-025-01779-7"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Monge-Argiles JA, Monge-Garcia V, Gasparini-Berenguer R, Garcia-Perez C, Gabaldon-Torres L, Salas-Felipe J, et al. Frequent involvement of the amyloid pathway in prodromal dementia with Lewy bodies. Revista De Neurologia. 2019; 69: 89\u201393.","DOI":"10.33588\/rn.6903.2019036"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Slaets S, Le Bastard N, Theuns J, Sleegers K, Verstraeten A, De Leenheir E, et al. Amyloid pathology influences a\u03b21-42 cerebrospinal fluid levels in dementia with lewy bodies. Journal of Alzheimer's Disease : JAD. 2013; 35: 137\u2013146.","DOI":"10.3233\/JAD-122176"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"van Steenoven I, Aarsland D, Weintraub D, Londos E, Blanc F, van der Flier WM, et al. Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. Journal of Alzheimer's Disease : JAD. 2016; 54: 287\u2013295.","DOI":"10.3233\/JAD-160322"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Abdelnour C, van Steenoven I, Londos E, Blanc F, Auestad B, Kramberger MG, et al. Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia. Movement Disorders : Official Journal of the Movement Disorder Society. 2016; 31: 1203\u20131208.","DOI":"10.1002\/mds.26668"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Hall S, Janelidze S, Londos E, Leuzy A, Stomrud E, Dage JL, et al. Plasma Phospho-Tau Identifies Alzheimer's Co-Pathology in Patients with Lewy Body Disease. Movement Disorders : Official Journal of the Movement Disorder Society. 2021; 36: 767\u2013771.","DOI":"10.1002\/mds.28370"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Warmenhoven N, Salvad\u00f3 G, Janelidze S, Mattsson-Carlgren N, Bali D, Ordu\u00f1a Dolado A, et al. A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests. Brain : a Journal of Neurology. 2025; 148: 416\u2013431.","DOI":"10.1093\/brain\/awae346"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Palmqvist S, Warmenhoven N, Anastasi F, Pilotto A, Janelidze S, Tideman P, et al. Plasma phospho-tau217 for Alzheimer's disease diagnosis in primary and secondary care using a fully automated platform. Nature Medicine. 2025; 31: 2036\u20132043.","DOI":"10.1038\/s41591-025-03622-w"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"O'Bryant SE, Gupta V, Henriksen K, Edwards M, Jeromin A, Lista S, et al. Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 2015; 11: 549\u2013560.","DOI":"10.1016\/j.jalz.2014.08.099"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Bittner T. Editorial: What Are the Remaining Challenges before Blood-Based Biomarkers for Alzheimer's Disease Can Be Used in Clinical Practice? The Journal of Prevention of Alzheimer's Disease. 2022; 9: 567\u2013568.","DOI":"10.14283\/jpad.2022.89"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Sch\u00f6ll M, Vrillon A, Ikeuchi T, Quevenco FC, Iaccarino L, Vasileva-Metodiev SZ, et al. Cutting through the noise: A narrative review of Alzheimer's disease plasma biomarkers for routine clinical use. The Journal of Prevention of Alzheimer's Disease. 2025; 12: 100056.","DOI":"10.1016\/j.tjpad.2024.100056"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Salvad\u00f3 G, Janelidze S, Bali D, Dolado AO, Therriault J, Brum WS, et al. Plasma Phosphorylated Tau 217 to Identify Preclinical Alzheimer Disease. JAMA Neurology. 2025; 82: 1122\u20131134.","DOI":"10.1001\/jamaneurol.2025.3217"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Janelidze S, Palmqvist S, Leuzy A, Stomrud E, Verberk IMW, Zetterberg H, et al. Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma A\u03b242\/A\u03b240 and p-tau. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 2022; 18: 283\u2013293.","DOI":"10.1002\/alz.12395"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Cullen NC, Janelidze S, Mattsson-Carlgren N, Palmqvist S, Bittner T, Suridjan I, et al. Test-retest variability of plasma biomarkers in Alzheimer's disease and its effects on clinical prediction models. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 2023; 19: 797\u2013806.","DOI":"10.1002\/alz.12706"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Sehrawat A, Zeng X, Abrahamson EE, Deek RA, Gogola A, Kamboh MI, et al. Pittsburgh plasma p-tau217: Classification accuracies for autosomal dominant and sporadic Alzheimer's disease in the community. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 2025; 21: e70409.","DOI":"10.1002\/alz.70409"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Pilotto A, Quaresima V, Trasciatti C, Tolassi C, Bertoli D, Mordenti C, et al. Plasma p-tau217 in Alzheimer's disease: Lumipulse and ALZpath SIMOA head-to-head comparison. Brain : a Journal of Neurology. 2025; 148: 408\u2013415.","DOI":"10.1093\/brain\/awae368"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Su\u00e1rez-Calvet M, Abdelnour C, Alcolea D, Mendi\u00f3roz-Iriarte M, Balasa M, Morenas-Rodr\u00edguez E, et al. Blood-based biomarkers for Alzheimer's disease: positioning document and usage recommendations from the Behavioral Neurology and Dementia Study Group of the Spanish Society of Neurology. Neurologia. 2025; 40: 700\u2013712.","DOI":"10.1016\/j.nrleng.2025.07.004"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Selma-Gonzalez J, Rubio-Guerra S, Garc\u00eda-Castro J, Vera-Campuzano E, Sala I, S\u00e1nchez-Saudin\u00f3s MB, et al. Association of Plasma Phosphorylated Tau 217 With Clinical Deterioration Across Alzheimer Disease Stages. Neurology. 2025; 105: e213769.","DOI":"10.1212\/WNL.0000000000213769"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Huber H, Montoliu-Gaya L, Brum WS, V\u00e1vra J, Yakoub Y, Weninger H, et al. A minimally invasive dried blood spot biomarker test for the detection of Alzheimer's disease pathology. Nature Medicine. 2026; 32: 599\u2013608.","DOI":"10.1038\/s41591-025-04080-0"}],"container-title":["Revista de Neurolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RN\/81\/7\/10.31083\/RN50619","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:50:14Z","timestamp":1785412214000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RN\/81\/7\/10.31083\/RN50619"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026]]}},"alternative-id":["S0210-0010(26)00123-4"],"URL":"https:\/\/doi.org\/10.31083\/rn50619","relation":{},"ISSN":["0210-0010","1576-6578"],"issn-type":[{"value":"0210-0010","type":"print"},{"value":"1576-6578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"article-number":"50619"}}